Sanofi
HealthcareNASDAQ:SNY · NASDAQ Global Select
+$0.18 today
Vol 1.17M · Avg 2.81M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
10.9%
avg 9.7%
ROIC
7.7%
avg 6.2%
ROA
6.2%
avg 5.5%
Analysis
ROE is currently the strongest return metric at 10.9% versus its period average of 9.7%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Belen Garijo Lopez | Chief Executive Officer & Director | $4.72M | — | 66 | — | — |
Olivier Charmeil | Executive Vice President of General Medicines | — | — | 63 | — | — |
Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing | — | — | 69 | — | — |
Roy Papatheodorou | Executive Vice President & General Counsel | — | — | 48 | — | — |
Thomas Kudsk Larsen | Head of Investor Relations & General Medicines | — | — | 52 | — | — |
Thomas Triomphe | Executive Vice President of Vaccines | — | — | 52 | — | — |
Madeleine Roach | Executive Vice President & Head of Business Operations | — | — | 42 | — | — |
Natalie Bickford | Executive Vice President & Chief People Officer | — | — | 56 | — | — |
Fabrizio Gaudi | Head of Austrian, German & Swiss Operations | — | — | — | — | — |
Erik Wallström | Head of Therapeutic Area - Neurology Development | — | — | — | — | — |
François-Xavier Roger | Executive Vice President & Chief Financial Officer | — | — | 64 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -3.8% | +8.9% (15yr)5 analysts |
| Revenue | N/A | N/A | -1.0% | +3.5% (15yr)7 analysts |
| Net Income | N/A | N/A | -4.3% | +8.4% (15yr)7 analysts |
| EBIT | N/A | N/A | -4.4% | +4.6% (15yr)7 analysts |
Analysis
Recent growth has been strongest in Revenue at -1.0% over three years. Forward estimates point to EPS at +8.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Amgen Inc.
NASDAQ:AMGN
$190.74B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.36B
Pfizer Inc.
NYSE:PFE
$149.07B
CVS Health Corporation
NYSE:CVS
$129.95B
Bristol-Myers Squibb Company
NYSE:BMY
$116.55B
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
$112.69B
GSK plc
NYSE:GSK
$106.55B
Medtronic plc
NYSE:MDT
$103.10B
HCA Healthcare, Inc.
NYSE:HCA
$85.76B
Bristol-Myers Squibb Company Ce
CELG-RI
$250.97M
Who manages SNY?
Sanofi (SNY) lists 11 active executives. The top listed executive is Olivier Charmeil, Executive Vice President of General Medicines.
Explore More
Continue the stock analysis
Jump to another research area for this company.